Mab Biosimilars Market Size, Share, Strategies, Insights and Forecasts to 2020

Technavio Announces the Publication of its Research Report Global Monoclonal Antibody (mAb) Biosimilars Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Monoclonal Antibody (mAb) Biosimilars Market: Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan, Alvartis Pharma, Amega Biotech, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Bharat Serums, Bio Sidus, Biogen, Bionovis, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Boston Oncology, Cipla, Coherus Biosciences, Daiichi Sankyo, Emcure Pharmaceuticals, Gedeon Richter, GeneScience Pharmaceuticals, GSK, Hetero Drugs, iBio, Intas Pharmaceuticals, JCR Pharmaceuticals, LG Lifesciences, Lonza, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Mylan, Natco Pharma, Novartis, Pfenex, Pfizer, Ranbaxy Laboratories, Roche Holding, Samsung Biologics, Sanofi, and Synthon.

Browse full report with TOC@

Commenting on the report, an analyst from Technavios team said: One trend spurring growth is the emergence of biosimilars. At present, it has been observed that due to the increase in geriatric population, the prevalence of chronic diseases, such as rheumatoid arthritis, psoriatic arthritis, cancers, and metabolic disorders, has increased. As a result, Biosimilars will play a major role in this scenario. The increased sales of biosimilars are expected to pull down the sales of biologics during the forecast period.”

According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries. A biosimilar can be developed only after the patent expiry of the original product . Many first-generation biopharmaceuticals have expired or will expire during the forecast period. For instance, the patent of drugs such as Rituxan/MabThera, Remicade, Herceptin, Humira, Avastin,...